The overexpression of EZH2 in RCC associated with lymphocytic infiltration and high CD8+ density could navigate immune evasion and the poor patient outcome [16], supporting a treatment strategy aimed at downregulating EZH2. This evidence concerns the gene CD8A and renal cell carcinoma.